Effect of eNOS polymorphisms on salbutamol evoked endothelium dependent vasodilation in South Indian healthy subjects

Kumar, Srinivasamurthy Suresh; Kumar, Annan Sudarsan Arun; Padmapriya, Ramamoorthy; Chandrasekaran, Adithan

doi:10.4103/0253-7613.106427

Cited by 4 publications

(3 citation statements)

References 18 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The identification of the patients with these “slow” alleles can help to correct the dose of warfarin: these patients require lower doses of the drug to achieve a similar therapeutic effect compared to patients with a wild-type haplotype [ 65 ]. Similar situations are described for a variety of other drugs: pravastatin (polymorphisms of cholesterol ester transferase) [ 66 ], neuroleptics (polymorphisms of dopamine receptor D3) [ 67 ], hydrochlorothiazide (adducin polymorphism) [ 68 ], salbutamol (polymorphism of adrenergic receptor) [ 69 ], etc. The results of these investigations have confirmed the importance of identifying the genetically determined reactions of an organism to medicine.…”

Section: Comparison Of Pharmacometabolomics and Pharmacogenomicsmentioning

confidence: 99%

A Metabolomics Approach to Pharmacotherapy Personalization

Balashova

Maslov

Lokhov

2018

JPM

View full text Add to dashboard Cite

The optimization of drug therapy according to the personal characteristics of patients is a perspective direction in modern medicine. One of the possible ways to achieve such personalization is through the application of “omics” technologies, including current, promising metabolomics methods. This review demonstrates that the analysis of pre-dose metabolite biofluid profiles allows clinicians to predict the effectiveness of a selected drug treatment for a given individual. In the review, it is also shown that the monitoring of post-dose metabolite profiles could allow clinicians to evaluate drug efficiency, the reaction of the host to the treatment, and the outcome of the therapy. A comparative description of pharmacotherapy personalization (pharmacogenomics, pharmacoproteomics, and therapeutic drug monitoring) and personalization based on the analysis of metabolite profiles for biofluids (pharmacometabolomics) is also provided.

show abstract

Section: Comparison Of Pharmacometabolomics and Pharmacogenomicsmentioning

confidence: 99%

A Metabolomics Approach to Pharmacotherapy Personalization

Balashova

Maslov

Lokhov

2018

JPM

View full text Add to dashboard Cite

show abstract

“…Схожие ситуации описаны и для целого ряда других лекарств: правастатина (полиморфизм белка-переносчика эфиров холестерина) [43], нейролептиков (полиморфизм дофаминового рецептора D3) [46], гидрохлортиазида (полиморфизм аддуцина) [47], сальбутамола (полиморфизм адренорецептора) [48] и т.д.…”

Section: сравнительный анализ фармакометабономики (фм) и фармакогенетunclassified

Pharmacometabonomics – the novel way to personalized drug therapy

et al. 2017

View full text Add to dashboard Cite

The review is devoted to pharmacometabonomics - a new branch of science focused on personalization of drug therapy through the comprehensive analysis of metabolites of patient's biological fluids. It considers the history of pharmacometabonomic, positioning to other "-omic" sciences, and system approach, realized by this science, in determination of individual therapeutic dose of the drugs and also a technical implementation of pharmacometabonomic based on direct mass spectrometry of blood plasma metabolites. Special attention is paid to a comparative analysis of pharmacometabonomics and other main approaches to personalized therapy in the clinic, such as pharmacogenetics and therapeutic drug monitoring. Finally, prospects of pharmacometabonomics applications in clinical practice were also discussed.

show abstract

“…The relationship between eNOS and endothelial dysfunction measured non-invasively was evidenced by Kumar et al in healthy subjects [25]. It is also known that nitric oxide can influence arterial stiffness by vascular tone regulation.…”

mentioning

confidence: 91%

The Relationship Between eNOS (G894T ) Gene Polymorphism and Arterial Stiffness in Patients with Metabolic Syndrome

Cozma¹,

Taut²,

Orășan³

et al. 2018

Rev. Chim.

View full text Add to dashboard Cite

Metabolic syndrome (MS) is a clustering entity characterized by obesity, hypertension, hyperglycemia, dyslipidemia, and insulin resistance. Atherosclerotic lesions may be a complication of MS, arising from endothelial dysfunction and induced by decreased nitric oxide (NO) production. NO is synthesized by nitric oxide synthase (eNOS), encoded by the NOS3 gene, and displays anti-inflammatory, vasodilatory, and antiproliferative effects.We aimed to investigate the relationship between the G894T polymorphism of the eNOS gene and metabolic syndrome (including its components) and the association of this polymorphism with arterial function, assessed by determining pulse wave velocity and the augmentation index.The study included 100 consecutive patients, 55% with metabolic syndrome (based on IDF criteria -study group), 45% without MS (control group). Arterial stiffness was measured using TensioMedTMArteriograph. The presence of the homozygous (TT) or heterozygous (GT) state was associated, compared to subjects without the mutation (GG), with an increased prevalence of arterial hypertension, diabetes mellitus, with an increase of abdominal circumference, an increase of triglycerides, without significantly influencing the level of HDL. No significant differences were found between patients with G894T polymorphism compared to those without the mutation regarding the arterial stiffness. The eNOS gene polymorphism: 894G]T was significantly associated with the presence of MS; the polymorphism in homozygous and heterozygous state was associated with an increased risk of metabolic syndrome. G894T polymorphism did not significantly influence the values of the studied arterial parameters (pulse wave velocity, aortic and brachial augmentation index).

show abstract

Effect of eNOS polymorphisms on salbutamol evoked endothelium dependent vasodilation in South Indian healthy subjects

Cited by 4 publications

References 18 publications

A Metabolomics Approach to Pharmacotherapy Personalization

A Metabolomics Approach to Pharmacotherapy Personalization

Pharmacometabonomics – the novel way to personalized drug therapy

The Relationship Between eNOS (G894T ) Gene Polymorphism and Arterial Stiffness in Patients with Metabolic Syndrome

Contact Info

Product

Resources

About